Global Health VenturesBegins Testing of Nico-Z (TM). Its Sublingual Nicotine Film at the University of British Columbia

VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 12, 2009) - Global Health Ventures Inc. (OTCBB: GHLV), or the “Company” a Specialty Pharma is pleased to announce the start of a series of pharmaceutical tests on “Nico-ZTM”, it’s sublingual formulation product of nicotine. The product is placed under the tongue which allows for a rapid and highly efficient absorption. The Pharmaceutical School of the University of British Columbia in Vancouver is famous for it’s top level testing and new formulations of drugs, biological and consumer products. The Company’s tests will examine product stability, taste, absorption rates and efficiency. This is a key part of the final stage of the prototype preparation.

About Nico-ZTM

Nico-ZTM is one of the Company’s most advanced products designed for smoking cessation and/or a replacement for addiction to cigarette’s and other tobacco products. For people craving for a cigarette, but in an environment which does not allow smoking, Nico-ZTM can immediately reduce the craving and the needs for smoking. It is in the form of a thin film paced under the tongue and within seconds the product absorbs into the blood. While there are currently nicotine based products on the market, none of them have the convenience and rapid action that our sublingual product Nico-ZTM has. The nicotine patch is slow and very inconvenient, as well as costly. While gum is inexpensive, it has a very low absorption profile. The nicotine inhalers are expensive and very much regulated. The need for a convenient, low cost and fast acting formulation is highly desirable and the Company believes it will be able to take a large share of the market. Currently it is estimated the nicotine based products have a market of $1.5 billon.

About Global Health Ventures Inc.

Global Health Ventures, Inc. (the “Company”) is a specialty pharma with focus on the Over-The-Counter market. The Company has a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy. The Company currently has five products in late stage development and several more underway.

Safe Harbor Statement

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company’s filings (10K) with the Securities and Exchange Commission.